Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

- PMLiVE

BMS aims for US approval of Opdivo combo in stomach cancer

US regulator has set a goal date for a decision on 25 May

- PMLiVE

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

Competition heats up with rival checkpoint inhibitor Keytruda

- PMLiVE

FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

Inspection of third-party manufacturing plant delayed due to COVID-19

- PMLiVE

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

Acquisition will bolster pipeline with targeted cardiovascular therapies

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

- PMLiVE

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

Agreement will focus on development in oncology and haematology

- PMLiVE

BMS pledges $300m to tackle health inequity and improve diversity

Drugmaker announces a series of commitments to expand inclusion

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links